Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Effectiveness Study of Intraspinal Gabapentin (MDT2004) for the Treatment of Chronic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic pain below the neck present for a minimum of one year.~* Diagnosis of at least one of the following:~  * back pain with or without leg pain,~ * post-herpetic neuralgia,~ * complex regional pain syndrome (CRPS) 1 or 2,~ * diabetic neuropathy,~ * or a general neuropathic condition; medically stable and able to undergo surgery for implantation of the drug infusion system.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (0mg/day) (Type: PLACEBO_COMPARATOR): Intraspinal Placebo delivered continuously for 29 days via an implantable infusion system
- Gabapentin Low (1mg/day) (Type: ACTIVE_COMPARATOR): Intraspinal Gabapentin Low delivered continuously for 22 days via an implantable infusion system followed by 7 days infusion at half dose
- Gabapentin Medium (6mg/day) (Type: ACTIVE_COMPARATOR): Intraspinal Gabapentin Medium delivered continuously for 22 days via an implantable infusion system followed by 7 days infusion at half dose
- Gabapentin High (30mg/day) (Type: ACTIVE_COMPARATOR): Intraspinal Gabapentin High delivered continuously for 22 days via an implantable infusion system followed by 7 days infusion at half dose

Based on this trial design, predict the completion outcome and termination type (if applicable).